Novavax COVID-19 Vaccine

Overview

COVID-19 vaccine

vaccine

• non-live vaccine

Avoid/Use Alternative

• interferon gamma 1b
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

interferon gamma 1b

1 interaction

Avoid/Use Alternative

COVID-19 vaccine + interferon gamma 1b

avoid combo: combo may result in amplified immune response (immunomodulatory effects)

Monitor/Modify Tx

• abatacept
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

abatacept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + abatacept

if possible, vaccinate at least 2wk before starting abatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abemaciclib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

abemaciclib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + abemaciclib

if possible, vaccinate at least 2wk before starting abemaciclib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abrocitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

abrocitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + abrocitinib

if possible, vaccinate at least 2wk before starting abrocitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• acalabrutinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

acalabrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + acalabrutinib

if possible, vaccinate at least 2wk before starting acalabrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• adalimumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

adalimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + adalimumab

if possible, vaccinate at least 2wk before starting adalimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• afamitresgene autoleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + afamitresgene autoleucel

if possible, vaccinate at least 2wk before starting afamitresgene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• aldesleukin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

aldesleukin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + aldesleukin

if possible, vaccinate at least 2wk before starting aldesleukin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• alemtuzumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

alemtuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + alemtuzumab

if possible, vaccinate at least 4wk before starting alemtuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anakinra
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

anakinra

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + anakinra

if possible, vaccinate at least 2wk before starting anakinra tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anifrolumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

anifrolumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + anifrolumab

if possible, vaccinate at least 2wk before starting anifrolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + anti-thymocyte globulin

if possible, vaccinate at least 4wk before starting anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atezolizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

atezolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + atezolizumab

if possible, vaccinate at least 2wk before starting atezolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atidarsagene autotemcel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + atidarsagene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• avelumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

avelumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + avelumab

if possible, vaccinate at least 2wk before starting avelumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• axicabtagene ciloleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + axicabtagene ciloleucel

if possible, vaccinate at least 2wk before starting axicabtagene ciloleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azacitidine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

azacitidine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + azacitidine

if possible, vaccinate at least 2wk before starting azacitidine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azathioprine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

azathioprine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + azathioprine

if possible, vaccinate at least 2wk before starting azathioprine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• baricitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

baricitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + baricitinib

if possible, vaccinate at least 2wk before starting baricitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• basiliximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

basiliximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + basiliximab

if possible, vaccinate at least 2wk before starting basiliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bebtelovimab (LY-CoV1404)
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bebtelovimab (LY-CoV1404)

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bebtelovimab (LY-CoV1404)

consider vaccinating at least 90 days after bebtelovimab tx: combo may result in inadequate vaccine response (antagonistic effects)

• belatacept
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belatacept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belatacept

if possible, vaccinate at least 2wk before starting belatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belimumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belimumab

if possible, vaccinate at least 4wk before starting belimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belinostat
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

belinostat

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + belinostat

if possible, vaccinate at least 2wk before starting belinostat tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bendamustine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bendamustine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bendamustine

if possible, vaccinate at least 2wk before starting bendamustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• betamethasone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

betamethasone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + betamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• bimekizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bimekizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bimekizumab

if possible, vaccinate at least 2wk before starting bimekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• blinatumomab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

blinatumomab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + blinatumomab

if possible, vaccinate at least 4wk before starting blinatumomab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bortezomib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

bortezomib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + bortezomib

if possible, vaccinate at least 2wk before starting bortezomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brentuximab vedotin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + brentuximab vedotin

if possible, vaccinate at least 4wk before starting brentuximab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brexucabtagene autoleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + brexucabtagene autoleucel

if possible, vaccinate at least 2wk before starting brexucabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brodalumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

brodalumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + brodalumab

if possible, vaccinate at least 2wk before starting brodalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

budesonide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + budesonide

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide rectal
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

budesonide rectal

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + budesonide rectal

consider vaccinating at least 2wk before budesonide rectal use; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• busulfan
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

busulfan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + busulfan

if possible, vaccinate at least 2wk before starting busulfan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cabazitaxel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cabazitaxel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cabazitaxel

if possible, vaccinate at least 2wk before starting cabazitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• canakinumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

canakinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + canakinumab

if possible, vaccinate at least 2wk before starting canakinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capecitabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

capecitabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + capecitabine

if possible, vaccinate at least 2wk before starting capecitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carboplatin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

carboplatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + carboplatin

if possible, vaccinate at least 2wk before starting carboplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carfilzomib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

carfilzomib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + carfilzomib

if possible, vaccinate at least 2wk before starting carfilzomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carmustine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

carmustine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + carmustine

if possible, vaccinate at least 2wk before starting carmustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• casirivimab (REGN10933)
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

casirivimab (REGN10933)

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + casirivimab (REGN10933)

consider vaccinating at least 90 days after casirivimab tx: combo may result in inadequate vaccine response (antagonistic effects)

• cemiplimab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cemiplimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cemiplimab

if possible, vaccinate at least 2wk before starting cemiplimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• certolizumab pegol
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + certolizumab pegol

if possible, vaccinate at least 2wk before starting certolizumab pegol tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorambucil
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

chlorambucil

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + chlorambucil

if possible, vaccinate at least 2wk before starting chlorambucil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cilgavimab (AZD1061)
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cilgavimab (AZD1061)

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cilgavimab (AZD1061)

admin. cilgavimab at least 2wk after vaccine: combo may result in inadequate vaccine response (antagonistic effects)

• ciltacabtagene autoleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ciltacabtagene autoleucel

if possible, vaccinate at least 2wk before starting ciltacabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cisplatin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cisplatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cisplatin

if possible, vaccinate at least 2wk before starting cisplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine injection
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cladribine injection

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cladribine injection

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine oral
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cladribine oral

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cladribine oral

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• clofarabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

clofarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + clofarabine

if possible, vaccinate at least 2wk before starting clofarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• copanlisib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

copanlisib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + copanlisib

if possible, vaccinate at least 2wk before starting copanlisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• corticotropin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

corticotropin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + corticotropin

if possible, vaccinate at least 2wk before starting corticotropin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cortisone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cortisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• cosibelimab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cosibelimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cosibelimab

if possible, vaccinate at least 2wk before starting cosibelimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cyclophosphamide

if possible, vaccinate at least 2wk before starting cyclophosphamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclosporine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cyclosporine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cyclosporine

if possible, vaccinate at least 2wk before starting cyclosporine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cytarabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

cytarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + cytarabine

if possible, vaccinate at least 2wk before starting cytarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dactinomycin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dactinomycin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dactinomycin

if possible, vaccinate at least 2wk before starting dactinomycin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daratumumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

daratumumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + daratumumab

if possible, vaccinate at least 4wk before starting daratumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dasatinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dasatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dasatinib

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daunorubicin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

daunorubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + daunorubicin

if possible, vaccinate at least 2wk before starting daunorubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• decitabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

decitabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + decitabine

if possible, vaccinate at least 2wk before starting decitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deflazacort
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

deflazacort

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + deflazacort

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• deucravacitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

deucravacitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + deucravacitinib

if possible, vaccinate at least 2wk before starting deucravacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deuruxolitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + deuruxolitinib

if possible, vaccinate at least 2wk before starting deuruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dexamethasone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dexamethasone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dexamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• dimethyl fumarate
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dimethyl fumarate

if possible, vaccinate at least 2wk before starting dimethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dinutuximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dinutuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dinutuximab

if possible, vaccinate at least 2wk before starting dinutuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diroximel fumarate
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + diroximel fumarate

if possible, vaccinate at least 2wk before starting diroximel fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• docetaxel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

docetaxel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + docetaxel

if possible, vaccinate at least 2wk before starting docetaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dostarlimab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dostarlimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dostarlimab

if possible, vaccinate at least 2wk before starting dostarlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• doxorubicin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

doxorubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + doxorubicin

if possible, vaccinate at least 2wk before starting doxorubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dupilumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

dupilumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + dupilumab

if possible, vaccinate at least 2wk before starting dupilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• durvalumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

durvalumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + durvalumab

if possible, vaccinate at least 2wk before starting durvalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• duvelisib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

duvelisib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + duvelisib

if possible, vaccinate at least 2wk before starting duvelisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• efgartigimod alfa
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

efgartigimod alfa

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + efgartigimod alfa

if possible, vaccinate at least 2wk before starting efgartigimod alfa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elivaldogene autotemcel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + elivaldogene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• elotuzumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

elotuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + elotuzumab

if possible, vaccinate at least 2wk before starting elotuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elranatamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

elranatamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + elranatamab

if possible, vaccinate at least 4wk before starting elranatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• emapalumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

emapalumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + emapalumab

if possible, vaccinate at least 2wk before starting emapalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epcoritamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

epcoritamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + epcoritamab

if possible, vaccinate at least 4wk before starting epcoritamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epirubicin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

epirubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + epirubicin

if possible, vaccinate at least 2wk before starting epirubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• eribulin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

eribulin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + eribulin

if possible, vaccinate at least 2wk before starting eribulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etanercept
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etanercept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etanercept

if possible, vaccinate at least 2wk before starting etanercept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etoposide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etoposide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etoposide

if possible, vaccinate at least 2wk before starting etoposide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etrasimod
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

etrasimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + etrasimod

if possible, vaccinate at least 2wk before starting etrasimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• everolimus
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

everolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + everolimus

if possible, vaccinate at least 2wk before starting everolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fingolimod
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fingolimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fingolimod

if possible, vaccinate at least 2wk before starting fingolimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• floxuridine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

floxuridine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + floxuridine

if possible, vaccinate at least 2wk before starting floxuridine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludarabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fludarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fludarabine

if possible, vaccinate at least 2wk before starting fludarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludrocortisone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fludrocortisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fludrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• fluorouracil
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fluorouracil

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fluorouracil

if possible, vaccinate at least 2wk before starting fluorouracil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fruquintinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

fruquintinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + fruquintinib

if possible, vaccinate at least 2wk before starting fruquintinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemcitabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

gemcitabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + gemcitabine

if possible, vaccinate at least 2wk before starting gemcitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemtuzumab ozogamicin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + gemtuzumab ozogamicin

if possible, vaccinate at least 2wk before starting gemtuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• glofitamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

glofitamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + glofitamab

if possible, vaccinate at least 4wk before starting glofitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• golimumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

golimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + golimumab

if possible, vaccinate at least 2wk before starting golimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• guselkumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

guselkumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + guselkumab

if possible, vaccinate at least 2wk before starting guselkumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrocortisone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

hydrocortisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + hydrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxyurea
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

hydroxyurea

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + hydroxyurea

if possible, vaccinate at least 2wk before starting hydroxyurea tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibritumomab tiuxetan
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ibritumomab tiuxetan

if possible, vaccinate at least 4wk before starting ibritumomab tiuxetan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibrutinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ibrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ibrutinib

if possible, vaccinate at least 2wk before starting ibrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idarubicin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

idarubicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + idarubicin

if possible, vaccinate at least 2wk before starting idarubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idecabtagene vicleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + idecabtagene vicleucel

if possible, vaccinate at least 2wk before starting idecabtagene vicleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idelalisib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

idelalisib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + idelalisib

if possible, vaccinate at least 2wk before starting idelalisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ifosfamide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ifosfamide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ifosfamide

if possible, vaccinate at least 2wk before starting ifosfamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• imatinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

imatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + imatinib

if possible, vaccinate at least 2wk before starting imatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• imdevimab (REGN10987)
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

imdevimab (REGN10987)

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + imdevimab (REGN10987)

consider vaccinating at least 90 days after imdevimab tx: combo may result in inadequate vaccine response (antagonistic effects)

• inebilizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

inebilizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + inebilizumab

if possible, vaccinate at least 4wk before starting inebilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• infliximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

infliximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + infliximab

if possible, vaccinate at least 2wk before starting infliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + inotuzumab ozogamicin

if possible, vaccinate at least 4wk before starting inotuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ipilimumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ipilimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ipilimumab

if possible, vaccinate at least 2wk before starting ipilimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• irinotecan
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

irinotecan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + irinotecan

if possible, vaccinate at least 2wk before starting irinotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• isatuximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

isatuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + isatuximab

if possible, vaccinate at least 4wk before starting isatuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixabepilone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ixabepilone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ixabepilone

if possible, vaccinate at least 2wk before starting ixabepilone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixekizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ixekizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ixekizumab

if possible, vaccinate at least 2wk before starting ixekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lebrikizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lebrikizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lebrikizumab

if possible, vaccinate at least 2wk before starting lebrikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• leflunomide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

leflunomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + leflunomide

if possible, vaccinate at least 2wk before starting leflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lenalidomide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lenalidomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lenalidomide

if possible, vaccinate at least 2wk before starting lenalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lisocabtagene maraleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lisocabtagene maraleucel

if possible, vaccinate at least 2wk before starting lisocabtagene maraleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lomustine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lomustine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lomustine

if possible, vaccinate at least 2wk before starting lomustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• loncastuximab tesirine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + loncastuximab tesirine

if possible, vaccinate at least 4wk before starting loncastuximab tesirine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + lymphocyte immune globulin, anti-thymocyte globulin

if possible, vaccinate at least 4wk before starting anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• melphalan
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

melphalan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + melphalan

if possible, vaccinate at least 2wk before starting melphalan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mercaptopurine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mercaptopurine

if possible, vaccinate at least 2wk before starting mercaptopurine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methotrexate
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

methotrexate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + methotrexate

if possible, vaccinate at least 2wk before starting methotrexate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methylprednisolone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

methylprednisolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + methylprednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• mirikizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mirikizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mirikizumab

if possible, vaccinate at least 2wk before starting mirikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitoxantrone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mitoxantrone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mitoxantrone

if possible, vaccinate at least 2wk before starting mitoxantrone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mogamulizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mogamulizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mogamulizumab

if possible, vaccinate at least 2wk before starting mogamulizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• momelotinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

momelotinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + momelotinib

if possible, vaccinate at least 2wk before starting momelotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• monomethyl fumarate
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + monomethyl fumarate

if possible, vaccinate at least 2wk before starting monomethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mosunetuzumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mosunetuzumab

if possible, vaccinate at least 4wk before starting mosunetuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolate mofetil
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mycophenolate mofetil

if possible, vaccinate at least 2wk before starting mycophenolate mofetil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolic acid
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + mycophenolic acid

if possible, vaccinate at least 2wk before starting mycophenolic acid tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• natalizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

natalizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + natalizumab

if possible, vaccinate at least 2wk before starting natalizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nelarabine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nelarabine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nelarabine

if possible, vaccinate at least 2wk before starting nelarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nemolizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nemolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nemolizumab

if possible, vaccinate at least 2wk before starting nemolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nivolumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

nivolumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + nivolumab

if possible, vaccinate at least 2wk before starting nivolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obecabtagene autoleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + obecabtagene autoleucel

if possible, vaccinate at least 2wk before starting obecabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obinutuzumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

obinutuzumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + obinutuzumab

if possible, vaccinate at least 4wk before starting obinutuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ocrelizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ocrelizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ocrelizumab

if possible, vaccinate at least 4wk before starting ocrelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ofatumumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ofatumumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ofatumumab

if possible, vaccinate at least 4wk before starting ofatumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• omacetaxine mepesuccinate
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

omacetaxine mepesuccinate

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + omacetaxine mepesuccinate

if possible, vaccinate at least 2wk before starting omacetaxine mepesuccinate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• oxaliplatin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

oxaliplatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + oxaliplatin

if possible, vaccinate at least 2wk before starting oxaliplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ozanimod
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ozanimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ozanimod

if possible, vaccinate at least 2wk before starting ozanimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• paclitaxel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

paclitaxel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + paclitaxel

if possible, vaccinate at least 2wk before starting paclitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• panobinostat
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

panobinostat

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + panobinostat

if possible, vaccinate at least 2wk before starting panobinostat tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• peginterferon alfa 2a
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + peginterferon alfa 2a

if possible, vaccinate at least 2wk before starting peginterferon alfa 2a tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pembrolizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pembrolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pembrolizumab

if possible, vaccinate at least 2wk before starting pembrolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pemivibart
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pemivibart

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pemivibart

admin. pemivibart at least 2wk after vaccine: combo may result in inadequate vaccine response (antagonistic effects)

• pentostatin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pentostatin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pentostatin

if possible, vaccinate at least 2wk before starting pentostatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pirtobrutinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pirtobrutinib

if possible, vaccinate at least 2wk before starting pirtobrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• polatuzumab vedotin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + polatuzumab vedotin

if possible, vaccinate at least 4wk before starting polatuzumab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pomalidomide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

pomalidomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + pomalidomide

if possible, vaccinate at least 2wk before starting pomalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponatinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ponatinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ponatinib

if possible, vaccinate at least 2wk before starting ponatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponesimod
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ponesimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ponesimod

if possible, vaccinate at least 2wk before starting ponesimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisolone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

prednisolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + prednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

prednisone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + prednisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• procarbazine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

procarbazine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + procarbazine

if possible, vaccinate at least 2wk before starting procarbazine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• regorafenib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

regorafenib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + regorafenib

if possible, vaccinate at least 2wk before starting regorafenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• retifanlimab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

retifanlimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + retifanlimab

if possible, vaccinate at least 2wk before starting retifanlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilonacept
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rilonacept

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rilonacept

if possible, vaccinate at least 2wk before starting rilonacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• risankizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

risankizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + risankizumab

if possible, vaccinate at least 2wk before starting risankizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ritlecitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ritlecitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ritlecitinib

if possible, vaccinate at least 2wk before starting ritlecitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rituximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rituximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rituximab

vaccinate at least 4wk before starting rituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• romidepsin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

romidepsin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + romidepsin

if possible, vaccinate at least 2wk before starting romidepsin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ropeginterferon alfa-2b
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ropeginterferon alfa-2b

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ropeginterferon alfa-2b

if possible, vaccinate at least 2wk before starting ropeginterferon alfa-2b tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rozanolixizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

rozanolixizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + rozanolixizumab

if possible, vaccinate at least 2wk before starting rozanolixizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ruxolitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ruxolitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ruxolitinib

if possible, vaccinate at least 2wk before starting ruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sarilumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sarilumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sarilumab

if possible, vaccinate at least 2wk before starting sarilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• satralizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

satralizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + satralizumab

if possible, vaccinate at least 2wk before starting satralizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• secukinumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

secukinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + secukinumab

if possible, vaccinate at least 2wk before starting secukinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selinexor
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

selinexor

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + selinexor

if possible, vaccinate at least 2wk before starting selinexor tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siltuximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

siltuximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + siltuximab

if possible, vaccinate at least 2wk before starting siltuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siponimod
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

siponimod

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + siponimod

if possible, vaccinate at least 2wk before starting siponimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sirolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sirolimus

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus albumin-bound
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sirolimus albumin-bound

if possible, vaccinate at least 2wk before starting sirolimus albumin-bound tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus topical
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sirolimus topical

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sirolimus topical

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• smallpox vaccine, live
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

smallpox vaccine, live

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + smallpox vaccine, live

if possible, hold mRNA COVID-19 vaccine or protein subunit COVID-19 vaccine for at least 4wk after smallpox vaccine: combo may incr. risk of myocarditis (possible additive effects)

• smallpox/mpox vaccine, live
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + smallpox/ mpox vaccine, live

if possible, hold mRNA COVID-19 vaccine or protein subunit COVID-19 vaccine for at least 4wk after smallpox/mpox vaccine: combo may incr. risk of myocarditis (possible additive effects)

• sotrovimab (VIR-7831)
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sotrovimab (VIR-7831)

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sotrovimab (VIR-7831)

consider vaccinating at least 90 days after sotrovimab tx: combo may result in inadequate vaccine response (antagonistic effects)

• spesolimab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

spesolimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + spesolimab

if possible, vaccinate at least 2wk before starting spesolimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

sunitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + sunitinib

if possible, vaccinate at least 2wk before starting sunitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tacrolimus
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tacrolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tacrolimus

if possible, vaccinate at least 2wk before starting tacrolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tafasitamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tafasitamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tafasitamab

if possible, vaccinate at least 4wk before starting tafasitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• talquetamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

talquetamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + talquetamab

if possible, vaccinate at least 4wk before starting talquetamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tarlatamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tarlatamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tarlatamab

if possible, vaccinate at least 2wk before starting tarlatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teclistamab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

teclistamab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + teclistamab

if possible, vaccinate at least 4wk before starting teclistamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temozolomide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

temozolomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + temozolomide

if possible, vaccinate at least 2wk before starting temozolomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temsirolimus
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

temsirolimus

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + temsirolimus

if possible, vaccinate at least 2wk before starting temsirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teplizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

teplizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + teplizumab

vaccinate at least 2wk before or 6wk after teplizumab tx; otherwise, consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• teriflunomide
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

teriflunomide

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + teriflunomide

if possible, vaccinate at least 2wk before starting teriflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thioguanine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

thioguanine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + thioguanine

if possible, vaccinate at least 2wk before starting thioguanine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thiotepa
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

thiotepa

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + thiotepa

if possible, vaccinate at least 2wk before starting thiotepa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tildrakizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tildrakizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tildrakizumab

if possible, vaccinate at least 2wk before starting tildrakizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tisagenlecleucel
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tisagenlecleucel

if possible, vaccinate at least 2wk before starting tisagenlecleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tislelizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tislelizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tislelizumab

if possible, vaccinate at least 2wk before starting tislelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tixagevimab (AZD8895)
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tixagevimab (AZD8895)

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tixagevimab (AZD8895)

admin. tixagevimab at least 2wk after vaccine: combo may result in inadequate vaccine response (antagonistic effects)

• tocilizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tocilizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tocilizumab

if possible, vaccinate at least 2wk before starting tocilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tofacitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tofacitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tofacitinib

if possible, vaccinate at least 2wk before starting tofacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• topotecan
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

topotecan

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + topotecan

if possible, vaccinate at least 2wk before starting topotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• toripalimab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

toripalimab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + toripalimab

if possible, vaccinate at least 2wk before starting toripalimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tralokinumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tralokinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tralokinumab

if possible, vaccinate at least 2wk before starting tralokinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tremelimumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

tremelimumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + tremelimumab

if possible, vaccinate at least 2wk before starting tremelimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• triamcinolone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

triamcinolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + triamcinolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• ublituximab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ublituximab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ublituximab

if possible, vaccinate at least 4wk before starting ublituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• upadacitinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

upadacitinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + upadacitinib

if possible, vaccinate at least 2wk before starting upadacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ustekinumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

ustekinumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + ustekinumab

if possible, vaccinate at least 2wk before starting ustekinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vamorolone
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vamorolone

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vamorolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• vedolizumab
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vedolizumab

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vedolizumab

if possible, vaccinate at least 2wk before starting vedolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• venetoclax
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

venetoclax

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + venetoclax

if possible, vaccinate at least 4wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinblastine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vinblastine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vinblastine

if possible, vaccinate at least 2wk before starting vinblastine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vincristine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vincristine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vincristine

if possible, vaccinate at least 2wk before starting vincristine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinorelbine
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

vinorelbine

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + vinorelbine

if possible, vaccinate at least 2wk before starting vinorelbine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• voclosporin
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

voclosporin

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + voclosporin

if possible, vaccinate at least 2wk before starting voclosporin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanubrutinib
Novavax COVID-19 Vaccine (COVID-19 vaccine, protein subunit, adjuvanted (1vCOV-aPS))

+

zanubrutinib

1 interaction

Monitor/Modify Tx

COVID-19 vaccine + zanubrutinib

if possible, vaccinate at least 2wk before starting zanubrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)